Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol

Current Medical Research and Opinion

Volumn 23, Issue 2, 2007, Pages 275-284

  Murthy, Bindu P ^a   Skee, Donna M ^a   Danyluk, Alexander P ^b   Brett, Vincent ^b   Vorsanger, Gary J ^b   Moskovitz, Bruce L ^b  

^a Global Clinical Pharmacokinetics   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Conversion; Dosing titration; Extended release; Monte Carlo simulation; Pharmacokinetics; Switch; Tramadol; Transition

Indexed keywords

TRAMADOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG RELEASE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MONTE CARLO METHOD; PHASE 1 CLINICAL TRIAL; SIMULATION;

ANALGESICS, OPIOID; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; HUMANS; MODELS, CHEMICAL; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS; TRAMADOL;

EID: 33847394191     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162773     Document Type: Article

References (15)

1. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992;260:275-85
2. Tramadol - Biovail Corporation. Drugs R D 2004;5:182-3
3. Hair PI, Curran MP, Keam SJ. Tramadol extended-release tablets. Drugs 2006;66:2017-27
4. ULTRAM® ER (tramadol HCl) extended-release tablets: an oral once-daily formulation of tramadol. Formulary 2006;41(Suppl):1-17
5. ULTRAM® ER (tramadol HCl) extended-release tablets prescribing information. Raritan (NJ): PriCara, unit of Ortho-McNeil, Inc.; 2006
6. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
7. Gana TJ, Pascual MLG, Fleming RRB, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22:1391-401
8. Hing JP, Piotrovsky V, Kimko H, et al. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005;21:483-8
9. Eradiri O, Sista S, Lai JCK, et al. Bioavailability of extended-release and immediate-release formulations of tramadol HCl [abstract No. 126]. J Clin Pharmacol 2006;46:1091
10. Lai JCK, Sista S, Eradiri O. The pharmacokinetics of novel once daily tramadol hydrochloride extended release tablets in healthy subjects [abstract]. AAPS PharmSci 2003;5:M1071
11. Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997;35:469-74
12. ULTRAM® (tramadol hydrochloride tablets) prescribing information. Raritan (NJ): Ortho-McNeil Pharmaceutical, Inc.; 2004
13. Woody GE, Senay EC, Geller A, et al. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug Alcohol Depend 2003;72:163-8
14. Senay EC, Adams EH, Geller A, et al. Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003;69:233-41
15. McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol Suppl 2003;28:19-22